Francisco de Assis Acurcio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5210316/publications.pdf

Version: 2024-02-01

162 papers

3,561 citations

28 h-index 265206 42 g-index

218 all docs

218 docs citations

218 times ranked

4147 citing authors

#	Article	IF	CITATIONS
1	Economic evaluation of adalimumab versus etanercept for psoriatic arthritis in a Brazilian real-world model. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 473-479.	1.4	4
2	Acceptability and willingness to pay for a hypothetical vaccine against SARS CoV-2 by the Brazilian consumer: a cross-sectional study and the implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 119-129.	1.4	12
3	Social and economic factors associated with antidepressant use: Results of a national survey in primary care. Journal of Affective Disorders Reports, 2022, 8, 100307.	1.7	2
4	Functionality assessment in patients with rheumatic diseases undergoing treatment in the Public Health System. Einstein (Sao Paulo, Brazil), 2022, 20, eAO6453.	0.7	0
5	Conventional Synthetic Disease-Modifying Anti-rheumatic Drugs for Psoriatic Arthritis: Findings and Implications From a Patient Centered Longitudinal Study in Brazil. Frontiers in Pharmacology, 2022, 13, 878972.	3.5	2
6	Biological therapy in psoriatic arthritis patients with and without previous biologic experience. Medicina, 2022, 55, .	0.1	0
7	The Budget Impact of Monoclonal Antibodies Used to Treat Metastatic Colorectal Cancer in Minas Gerais, Brazil. Applied Health Economics and Health Policy, 2021, 19, 557-577.	2.1	2
8	Strategies to improve the availability of medicines in primary health care in Brazil: findings and implications. Journal of Comparative Effectiveness Research, 2021, 10, 243-253.	1.4	4
9	A cross-sectional study of the quality of life of patients living with type 1 diabetes treated with insulin glargine and neutral protamine Hagedorn insulin and the implications. Journal of Pharmaceutical Health Services Research, 2021, 12, 332-342.	0.6	3
10	Dezesseis Anos de Transplante CardÃaco em Coorte Aberta no Brasil: Análise de Sobrevivência de Pacientes em Uso de Imunossupressores. Arquivos Brasileiros De Cardiologia, 2021, 116, 744-753.	0.8	2
11	Influence of pharmaceutical services organization on the availability of essential medicines in a public health system. Journal of Comparative Effectiveness Research, 2021, 10, 519-532.	1.4	4
12	Effectiveness and safety of anti-TNF therapy for ankylosing spondylitis: a real-world study. Journal of Comparative Effectiveness Research, 2021, 10, 509-517.	1.4	3
13	Budget impact analysis of medicines: estimated values versus real-world evidence and the implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, , 1-11.	1.4	3
14	Medication adherence and persistence of psoriatic arthritis patients treated with biological therapy in a specialty pharmacy in Brazil: a prospective observational study. Pharmacy Practice, 2021, 19, 2312.	1.5	5
15	Access to medicines in the Brazilian Unified Health System's primary health care: assessment of a public policy. Journal of Comparative Effectiveness Research, 2021, 10, 869-879.	1.4	3
16	Cost-minimization analysis of teledermatology versus conventional care in the Brazilian National Health System. Journal of Comparative Effectiveness Research, 2021, 10, 1159-1168.	1.4	2
17	Health-Related Quality of Life in Psoriatic Arthritis: Findings and Implications. Value in Health Regional Issues, 2021, 26, 135-141.	1.2	8
18	Real-world effectiveness of olanzapine and risperidone in the treatment of schizophrenia in Brazil over a 16-year follow-up period; findings and implications. Expert Review of Clinical Pharmacology, 2021, 14, 269-279.	3.1	7

#	Article	IF	CITATIONS
19	A demographic and clinical panorama of a sixteen-year cohort of soft tissue sarcoma patients in Brazil. Scientific Reports, 2021, 11, 22501.	3.3	3
20	Cost Analysis of Cancer in Brazil: A Population-Based Study of Patients Treated by Public Health System From 2001-2015. Value in Health Regional Issues, 2020, 23, 137-147.	1.2	9
21	Integrative Review of Managed Entry Agreements: Chances and Limitations. Pharmacoeconomics, 2020, 38, 1165-1185.	3.3	25
22	Polypharmacy among adult and older adult users of primary care services delivered through the Unified Health System in Minas Gerais, Brazil. Expert Review of Clinical Pharmacology, 2020, 13, 1401-1409.	3.1	1
23	Cost-utility analysis of the anti-TNF therapy for rheumatoid arthritis in a real-world based model. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 21, 1-6.	1.4	4
24	Effectiveness of first-line treatment for relapsing-remitting multiple sclerosis in Brazil: A 16-year non-concurrent cohort study. PLoS ONE, 2020, 15, e0238476.	2.5	4
25	FIRST LINE OF SUBCUTANEOUS ANTI-TNF THERAPY FOR RHEUMATOID ARTHRITIS: A PROSPECTIVE COHORT STUDY. Expert Review of Clinical Immunology, 2020, 16, 1217-1225.	3.0	2
26	Realâ€world evaluation of the impact of statin intensity on adherence and persistence to therapy: A Scottish populationâ€based study. British Journal of Clinical Pharmacology, 2020, 86, 2349-2361.	2.4	16
27	Uso de medicamentos por adultos na atenção primária: inquérito em serviços de saúde de Minas Gerais, Brasil. Revista Brasileira De Epidemiologia, 2020, 23, e200025.	0.8	6
28	Academic detailing program for rheumatoid arthritis: a contribution to Brazilian public health system sustainability. Journal of Pharmaceutical Health Services Research, 2020, 11, 249-254.	0.6	3
29	Effectiveness of Maintenance Immunosuppression Therapies in a Matched-Pair Analysis Cohort of 16 Years of Renal Transplant in the Brazilian National Health System. International Journal of Environmental Research and Public Health, 2020, 17, 1974.	2.6	8
30	Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff. Hospital Practice (1995), 2020, 48, 213-222.	1.0	5
31	Comparative persistence of anti-tumor necrosis factor therapy in ankylosing spondylitis patients: a multicenter international study. Current Medical Research and Opinion, 2020, 36, 677-686.	1.9	13
32	Fatores de risco associados a náuseas e vÃ'mitos induzidos por quimioterapia antineoplásica. Revista De Saude Publica, 2020, 54, 106.	1.7	5
33	Polypharmacy, socioeconomic indicators and number of diseases: results from ELSA-Brasil. Revista Brasileira De Epidemiologia, 2020, 23, e200077.	0.8	17
34	Sixteen-Year Cohort of Liver Transplantation in the National Health System in Brazil: Analysis of Immunosuppression Maintenance Therapies. Frontiers in Pharmacology, 2020, 11, 572043.	3.5	1
35	Drug interactions in the elderly of the Unified Health System (SUS) in Brazil. European Journal of Public Health, 2020, 30, .	0.3	O
36	Who should pay for the continuity of post-trial health care treatments? International Journal for Equity in Health, 2019, 18, 26.	3.5	10

#	Article	IF	CITATIONS
37	Biological therapy in the treatment of psoriatic arthritis: economic and epidemiological considerations. Expert Review of Clinical Immunology, 2019, 15, 879-887.	3.0	14
38	(Un)Equitable distribution of health resources and the judicialization of healthcare: 10 years of experience in Brazil. International Journal for Equity in Health, 2019, 18, 10.	3.5	10
39	Confidentiality agreements: a challenge in market regulation. International Journal for Equity in Health, 2019, 18, 11.	3.5	8
40	Medication persistence for psoriatic arthritis in a Brazilian real-world setting. Future Science OA, 2019, 5, FSO369.	1.9	13
41	First line of biological drugs in rheumatoid arthritis: a medication persistence analysis. Expert Review of Clinical Pharmacology, 2019, 12, 363-370.	3.1	9
42	Health-related quality of life among HIV-infected patients initiating treatment in Brazil in the single-tablet regimen era. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 572-581.	1.2	11
43	Discontinuation, persistence and adherence to subcutaneous biologics delivered via a homecare route to Scottish adults with rheumatic diseases: a retrospective study. BMJ Open, 2019, 9, e027059.	1.9	10
44	Access to high-cost medications for psoriatic arthritis in the National Health System in Brazil: the long path up to dispensation. Advances in Rheumatology, 2019, 59, 48.	1.7	11
45	Indicator of access to medicines in relation to the multiple dimensions of access. Journal of Comparative Effectiveness Research, 2019, 8, 1027-1041.	1.4	12
46	Quality of Life of Patients with Type 1 Diabetes Mellitus Using Insulin Analog Glargine Compared with NPH Insulin: A Systematic Review and Policy Implications. Patient, 2018, 11, 377-389.	2.7	37
47	The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil. Pharmacoeconomics, 2018, 36, 161-173.	3.3	17
48	Effectiveness of antiretroviral therapy in the single-tablet regimen era. Revista De Saude Publica, 2018, 52, 87.	1.7	25
49	Cost-related underuse of medications in older adults. Revista De Saude Publica, 2018, 52, 8s.	1.7	10
50	Monitoring self-reported adherence to antiretroviral therapy in public HIV care facilities in Brazil. Medicine (United States), 2018, 97, S38-S45.	1.0	13
51	Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and) Tj ETQq1 1 0.784 Review and Meta-Analysis. BioDrugs, 2018, 32, 585-606.	314 rgBT 4.6	/Overlock 1 31
52	Effectiveness and safety of anti-TNF in psoriatic arthritis patients in Brazil: a post-incorporation analysis. Journal of Comparative Effectiveness Research, 2018, 7, 989-1000.	1.4	10
53	Effectiveness and safety of insulin glargine <i>versus</i> detemir analysis in patients with type 1 diabetes: systematic review and meta-analysis. Therapeutic Advances in Endocrinology and Metabolism, 2018, 9, 241-254.	3.2	12
54	Oral Hypoglycemic Drugs for Type 2 Diabetes Mellitus: Comparisson of Prices in Brazil and Other Universal Health Systems. Value in Health Regional Issues, 2018, 17, 135-141.	1.2	O

#	Article	IF	CITATIONS
55	The long-term costs for treating multiple sclerosis in a 16-year retrospective cohort study in Brazil. PLoS ONE, 2018, 13, e0199446.	2.5	19
56	Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil. Applied Health Economics and Health Policy, 2018, 16, 697-709.	2.1	23
57	Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 109-119.	1.4	13
58	The clinical effectiveness of insulin glargine in patients with Type I diabetes in Brazil: findings and implications. Journal of Comparative Effectiveness Research, 2017, 6, 519-527.	1.4	12
59	HEALTH TECHNOLOGY PERFORMANCE ASSESSMENT: REAL-WORLD EVIDENCE FOR PUBLIC HEALTHCARE SUSTAINABILITY. International Journal of Technology Assessment in Health Care, 2017, 33, 279-287.	0.5	32
60	Evaluation of primary health care by users and non-users of drugs hospitalized for primary care-sensitive conditions. Atencion Primaria, 2017, 49, 258-260.	1.4	2
61	Gender differences and psychotropic polypharmacy in psychiatric patients in Brazil: a cross-sectional analysis of the PESSOAS Project. Cadernos De Saude Publica, 2017, 33, e00168915.	1.0	15
62	Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia $\hat{A}^{\text{@}}$) in Brazil; Implications for Future Pricing Considerations. Frontiers in Pharmacology, 2017, 8, 41.	3.5	31
63	Pharmaceutical services in primary health care: interfederative agreement in the development of pharmaceutical policies in the Brazilian Unified Health System (SUS). Revista De Saude Publica, 2017, 51, 2s.	1.7	10
64	Patient survival and risk of death after prostate cancer treatment in the Brazilian Unified Health System. Revista De Saude Publica, 2017, 51, 46.	1.7	7
65	Health-related quality of life of patients of Brazilian primary health care. Revista De Saude Publica, 2017, 51, 22s.	1.7	20
66	Characterization of the selection of medicines for the Brazilian primary health care. Revista De Saude Publica, 2017, 51, 9s.	1.7	6
67	Infrastructure of pharmacies of the primary health care in the Brazilian Unified Health System:. Revista De Saude Publica, 2017, 51, 13s.	1.7	23
68	Access to medicines:. Revista De Saude Publica, 2017, 51, 8s.	1.7	13
69	Patient satisfaction with pharmaceutical services in Brazilian primary health care. Revista De Saude Publica, 2017, 51, 21s.	1.7	19
70	Management of pharmaceutical services in the Brazilian primary health care. Revista De Saude Publica, 2017, 51, 15s.	1.7	20
71	Use of medicines by patients of the primary health care of the Brazilian Unified Health System. Revista De Saude Publica, 2017, 51, 18s.	1.7	18
72	Financing of Pharmaceutical Services in the municipal management of the Brazilian Unified Health System. Revista De Saude Publica, 2017, 51, 14s.	1.7	11

#	Article	IF	CITATIONS
73	Access to medicines by patients of the primary health care in the Brazilian Unified Health System. Revista De Saude Publica, 2017, 51, 20s.	1.7	25
74	Characterization of the institutionalization of pharmaceutical services in Brazilian primary health care. Revista De Saude Publica, 2017, 51, 7s.	1.7	6
75	Pharmaceutical services in the primary health care of the Brazilian Unified Health System:. Revista De Saude Publica, 2017, 51, 3s.	1.7	14
76	Medicine dispensing service in primary health care of SUS. Revista De Saude Publica, 2017, 51, 11s.	1.7	23
77	Main characteristics of patients of primary health care services in Brazil. Revista De Saude Publica, 2017, 51, 17s.	1.7	44
78	Pharmaceutical care in Brazil's primary health care. Revista De Saude Publica, 2017, 51, 6s.	1.7	33
79	Polypharmacy:. Revista De Saude Publica, 2017, 51, 19s.	1.7	43
80	National Survey on Access, Use and Promotion of Rational Use of Medicines: methods. Revista De Saude Publica, 2017, 51, 4s.	1.7	37
81	Technical issues and conservation conditions of medicines in the primary health care of the Brazilian Unified Health System. Revista De Saude Publica, 2017, 51, 12s.	1.7	20
82	Availability of essential medicines in primary health care of the Brazilian Unified Health System. Revista De Saude Publica, 2017, 51, 10s.	1.7	44
83	Indicators related to the rational use of medicines and its associated factors. Revista De Saude Publica, 2017, 51, 23s.	1.7	30
84	Conceptions on pharmaceutical services in Brazilian primary health care. Revista De Saude Publica, 2017, 51, 5s.	1.7	12
85	Workforce in the pharmaceutical services of the primary health care of SUS, Brazil. Revista De Saude Publica, 2017, 51, 16s.	1.7	14
86	Improving community mobilization in HIV treatment management: practical suggestions from patients in Brazil. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2017, 41, e119.	1.1	1
87	Health self-assessment by hemodialysis patients in the Brazilian Unified Health System. Revista De Saude Publica, 2016, 50, 10.	1.7	17
88	Treatment persistence in patients with rheumatoid arthritis and ankylosing spondylitis. Revista De Saude Publica, 2016, 50, 50.	1.7	22
89	Implementation of clinical guidelines in Brazil: should academic detailing be used?. Journal of Pharmaceutical Health Services Research, 2016, 7, 105-115.	0.6	14
90	Ten-year kidney transplant survival of cyclosporine- or tacrolimus-treated patients in Brazil. Expert Review of Clinical Pharmacology, 2016, 9, 991-999.	3.1	15

#	Article	IF	CITATIONS
91	Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT ₃ RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis. Expert Review of Clinical Pharmacology, 2016, 9, 1183-1194.	3.1	11
92	Clinical Effectiveness and Safety of Analog Glargine in Type 1 Diabetes: A Systematic Review and Meta-Analysis. Diabetes Therapy, 2016, 7, 241-258.	2.5	21
93	Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System. Journal of Comparative Effectiveness Research, 2016, 5, 539-549.	1.4	13
94	Costs of Drug Therapy in Patients with Ankylosing Spondylitis in Brazil. Rheumatology and Therapy, 2016, 3, 353-361.	2.3	5
95	Medication Persistence of Diseaseâ€Modifying Antirheumatic Drugs and Anti–Tumor Necrosis Factor Agents in a Cohort of Patients With Rheumatoid Arthritis in Brazil. Arthritis Care and Research, 2016, 68, 1489-1496.	3.4	15
96	Real Life Experience of First Course of Anti-TNF Treatment in Ankylosing Spondylitis Patients in Brazil. Rheumatology and Therapy, 2016, 3, 143-154.	2.3	4
97	Quality of life of patients with Diabetes Mellitus Types 1 and 2 from a referal health centre in Minas Gerais, Brazil. Expert Review of Clinical Pharmacology, 2016, 9, 739-746.	3.1	30
98	Budget impact analysis of medicines: updated systematic review and implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 257-266.	1.4	31
99	Opioid Use and Risk of Nonvertebral Fractures in Adults With Rheumatoid Arthritis: A Nested Case–Control Study Using Administrative Databases. Arthritis and Rheumatology, 2016, 68, 83-91.	5.6	30
100	Cyclosporine versus tacrolimus: cost-effectiveness analysis for renal transplantation in Brazil. Revista De Saude Publica, 2015, 49, 13.	1.7	6
101	Gender in the allocation of organs in kidney transplants: meta-analysis. Revista De Saude Publica, 2015, 49, 68.	1.7	9
102	Factors Associated with Self-Reported Difficulty with Antiretrovial Therapy in Brazil: Gender Differences International Journal of Epidemiology, 2015, 44, i126-i127.	1.9	0
103	Profile of patients with rheumatic diseases undergoing treatment with anti-TNF agents in the Brazilian Public Health System (SUS), Belo Horizonte - MG. Brazilian Journal of Pharmaceutical Sciences, 2015, 51, 709-719.	1.2	4
104	Infliximabe, metotrexato e sua combinação no tratamento da artrite reumatoide: revisão sistemática e metanálise. Revista Brasileira De Reumatologia, 2015, 55, 146-158.	0.8	7
105	Poorer functionality is related to better quality of life response following the use of biological drugs: 6-month outcomes in a prospective cohort from the Public Health System (<i>Sistema Único de) Tj ETQq1 15, 403-412.</i>	1.2.78431	14 rgBT /Ove
106	Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?. Expert Review of Clinical Pharmacology, 2015, 8, 77-94.	3.1	108
107	Legal and health variations in drug litigation injunctions granted in Minas Gerais. Revista De Saude Publica, 2014, 48, 808-816.	1.7	6
108	Authors' Reply to Dr. Malerbi: "Insulin Glargine in a Brazilian State: Should the Government Disinvest?― Applied Health Economics and Health Policy, 2014, 12, 561-563.	2.1	2

#	Article	IF	CITATIONS
109	Rituximab for rheumatoid arthrits treatment: a systematic review. Revista Brasileira De Reumatologia, 2014, 54, 220-230.	0.7	1
110	Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety. Rheumatology International, 2014, 34, 1345-1360.	3.0	42
111	Insulin Glargine in a Brazilian State: Should the Government Disinvest? An Assessment Based on a Systematic Review. Applied Health Economics and Health Policy, 2014, 12, 19-32.	2.1	46
112	Adalimumab in rheumatoid arthritis treatment: a systematic review and meta-analysis of randomized clinical trials. Revista Brasileira De Reumatologia, 2013, 53, 419-430.	0.7	7
113	Adalimumabe no tratamento da artrite reumatoide: uma revisão sistemática e metanálise de ensaios clÃnicos randomizados. Revista Brasileira De Reumatologia, 2013, 53, 419-430.	0.8	3
114	Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatology International, 2013, 33, 2199-2213.	3.0	78
115	Safety of Immunosuppressive Drugs Used as Maintenance Therapy in Kidney Transplantation: A Systematic Review and Meta-Analysis. Pharmaceuticals, 2013, 6, 1170-1194.	3.8	25
116	Diálise planejada e a utilização regular da atenção primária à saúde entre os pacientes diabéticos do MunicÃpio de Belo Horizonte, Minas Gerais, Brasil. Cadernos De Saude Publica, 2013, 29, 1241-1250.	1.0	3
117	Indicador de subnotificação de óbitos no Sistema de Informação de Mortalidade no Brasil obtido de pacientes que morreram por doença renal crÃ′nica terminal: mensuração baseada nas Autorizações de Procedimentos de Alta Complexidade de 2000 a 2004. Cadernos Saude Coletiva, 2013, 21, 92-95.	0.6	3
118	Antivirais incorporados no Brasil para hepatite B cronica: analise de custo-efetividade. Revista De Saude Publica, 2013, 47, 769-780.	1.7	4
119	Avaliação normativa do processo de prescrição e dispensação de imunossupressores para pacientes transplantados renais no estado de Minas Gerais, Brasil, 2008. Epidemiologia E Servicos De Saude: Revista Do Sistema Unico De Saude Do Brasil, 2013, 22, 651-660.	1.0	3
120	Gender differences in non-adherence among Brazilian patients initiating antiretroviral therapy. Clinics, 2013, 68, 612-620.	1.5	29
121	Perfil e gastos dos pacientes dislipidêmicos usuários do componente especializado da assistência farmacêutica do Sistema Único de Saúde. Physis, 2013, 23, 1215-1227.	0.3	1
122	An \tilde{A}_i lise farmacoecon \tilde{A} ímica das estrat \tilde{A} ©gias de tratamento da osteoporose em mulheres na p \tilde{A}^3 s-menopausa: uma revis \tilde{A} £o sistem \tilde{A}_i tica. Revista Brasileira De Reumatologia, 2012, 52, 924-937.	0.8	11
123	Custo-efetividade dos análogos de nucleosÃdeos/nucleotÃdeos para hepatite crônica B. Revista De Saude Publica, 2012, 46, 942-949.	1.7	6
124	Evaluation of drug–drug interaction screening software combined with pharmacist intervention. International Journal of Clinical Pharmacy, 2012, 34, 547-552.	2.1	31
125	Quality of life of patients in renal replacement therapy in Brazil: comparison of treatment modalities. Quality of Life Research, 2012, 21, 983-991.	3.1	48
126	Factors associated with functional ability in Brazilian elderly. Archives of Gerontology and Geriatrics, 2012, 54, e89-e94.	3.0	37

#	Article	IF	CITATIONS
127	Nutritional assessment of patients undergoing hemodialysis at dialysis centers in Belo Horizonte, MG, Brazil. Revista Da Associação Médica Brasileira, 2012, 58, 240-247.	0.7	18
128	Chronic Hepatitis B Treatment: The Cost-Effectiveness of Interferon Compared to Lamivudin e. Value in Health, 2011, 14, S24-S28.	0.3	5
129	Judicialização do acesso a medicamentos no Estado de Minas Gerais, Brasil. Revista De Saude Publica, 2011, 45, 590-598.	1.7	77
130	Permanent vascular access in patients with end-stage renal disease, Brazil. Revista De Saude Publica, 2011, 45, 241-248.	1.7	5
131	Monitoring adherence to antiretroviral treatment in Brazil: an urgent challenge. Cadernos De Saude Publica, 2011, 27, s67-s78.	1.0	25
132	Fatores associados com a qualidade de vida relacionada à saúde de idosos em hemodiálise. Revista De Saude Publica, 2011, 45, 1127-1136.	1.7	36
133	Duration of temporary catheter use for hemodialysis: an observational, prospective evaluation of renal units in Brazil. BMC Nephrology, 2011, 12, 63.	1.8	10
134	Judicialização do acesso a medicamentos no Estado de Minas Gerais, Brasil . Revista De Saude Publica, 2011, 45, 590-598.	1.7	11
135	Iniquities in the access to renal transplant for patients with end-stage chronic renal disease in Brazil. Cadernos De Saude Publica, 2011, 27, s284-s297.	1.0	9
136	Uma avalia \tilde{A} § \tilde{A} £o da satisfa \tilde{A} § \tilde{A} £o de pacientes em hemodi \tilde{A} ¡lise cr \tilde{A} ´nica com o tratamento em servi \tilde{A} §os de di \tilde{A} ¡lise no Brasil. Physis, 2011, 21, 581-600.	0.3	6
137	Individual and Treatment Setting Predictors of HIV/AIDS Knowledge Among Psychiatric Patients and Their Implications In a National Multisite Study in Brazil. Community Mental Health Journal, 2010, 46, 505-516.	2.0	18
138	Perfil epidemiol \tilde{A}^3 gico dos pacientes em terapia renal substitutiva no Brasil, 2000-2004. Revista De Saude Publica, 2010, 44, 639-649.	1.7	47
139	Cyclosporine Versus Tacrolimus in Immunosuppressive Maintenance Regimens in Renal Transplants in Brazil: Survival Analysis from 2000 to 2004. Annals of Pharmacotherapy, 2010, 44, 192-199.	1.9	16
140	Allocation of Initial Modality for Renal Replacement Therapy in Brazil. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 637-644.	4.5	20
141	Decentralisation of leprosy control activities in the municipality of Betim, Minas Gerais State, Brazil. Leprosy Review, 2010, 81, 184-195.	0.3	4
142	Factors which influenced the decentralisation of leprosy control activities in the municipality of Betim, Minas Gerais State, Brazil. Leprosy Review, 2010, 81, 196-205.	0.3	5
143	Acurácia de informações sobre classes de medicamentos obtidas com questionário postal aplicado a idosos - Rio de Janeiro, RJ. Revista Brasileira De Epidemiologia, 2009, 12, 578-590.	0.8	0
144	Drug-Drug Interactions Associated with Length of Stay and Cost of Hospitalization. Journal of Pharmacy and Pharmaceutical Sciences, 2009, 12, 266.	2.1	157

#	Article	IF	CITATIONS
145	Prevalence of HIV, syphilis, hepatitis B and C among adults with mental illness: a multicenter study in Brazil. Revista Brasileira De Psiquiatria, 2009, 31, 43-47.	1.7	45
146	Drug-related problems observed in a pharmaceutical care service, Belo Horizonte, Brazil. Brazilian Journal of Pharmaceutical Sciences, 2009, 45, 321-330.	1.2	19
147	Perfil demográfico e epidemiológico dos usuários de medicamentos de alto custo no Sistema Único de Saúde. Revista Brasileira De Estudos De Populacao, 2009, 26, 263-282.	0.3	19
148	Drug utilization and polypharmacy among the elderly: a survey in Rio de Janeiro City, Brazil. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2008, 23, 34-43.	1.1	60
149	Reliability and validity of a questionnaire on vulnerability to sexually transmitted infections among adults with chronic mental illness: PESSOAS Project. Revista Brasileira De Psiquiatria, 2008, 30, 55-59.	1.7	24
150	Treatment of postmenopausal osteoporosis in women: a systematic review. Cadernos De Saude Publica, 2008, 24, s592-s606.	1.0	15
151	Inquérito sobre uso de medicamentos por idosos aposentados, Belo Horizonte,MG. Revista De Saude Publica, 2008, 42, 724-732.	1.7	41
152	Self-reported adverse reactions among patients initiating antiretroviral therapy in Brazil. Brazilian Journal of Infectious Diseases, 2007, 11, 20-6.	0.6	23
153	A construção da base de dados nacional em Terapia Renal Substitutiva (TRS) centrada no indivÃduo: aplicação do método de linkage determinÃstico-probabilÃstico. Revista Brasileira De Estudos De Populacao, 2007, 24, .	0.3	26
154	High incidence of adverse reactions to initial antiretroviral therapy in Brazil. Brazilian Journal of Medical and Biological Research, 2006, 39, 495-505.	1.5	30
155	Non-adherence among patients initiating antiretroviral therapy: a challenge for health professionals in Brazil. Aids, 2005, 19, S5-S13.	2.2	81
156	Analysis of medical prescriptions dispensed at health centers in Belo Horizonte, Minas Gerais, Brazil. Cadernos De Saude Publica, 2004, 20, 72-79.	1.0	20
157	Health care utilization and survival among patients with AIDS in Belo Horizonte, Minas Gerais, Brazil. Cadernos De Saude Publica, 1998, 14, 811-820.	1.0	17
158	Avaliaçã0 da qualidade dos serviços de saúde: notas bibliográficas. Cadernos De Saude Publica, 1990, 6, 50-61.	1.0	25
159	Utilização de fitoterápicos por idosos: resultados de um inquérito domiciliar em Belo Horizonte (MG), Brasil. Revista Brasileira De Farmacognosia, 0, 18, 754-760.	1.4	27
160	Target of rapamycin inhibitors (TORi) as maintenance immunosuppression for kidney transplant recipients. The Cochrane Library, 0, , .	2.8	0
161	Sobrevivência especÃfica de pacientes com câncer de pulmão tratados no sistema público de saúde no Brasil e uma aplicação da Tábua Associada de Decremento Único. Revista Brasileira De Estudos De Populacao, 0, 30, S193-S198.	0.3	0
162	A Cross-Sectional Study of Quality of Life Among Brazilian Adults With Type 1 Diabetes Treated With Insulin Glargine: Findings and Implications. Clinical Diabetes, 0, , .	2.2	0